Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
Class/mechanism: Radioligand therapeutic agent. The radionucleotide lutetium-177 is linked to vipivotide tetraxetan, which binds to PSMA (prostate-specific membrane antigen), a transmembrane protein that is expressed in prostate cancer. Binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-positive cells results in delivery of beta-minus radiation, resulting in DNA damage and cell death. Lutetium 177's half-life is 6.647 days.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2022-03-23: FDA approved for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. (Based on VISIONPrCA)
History of changes in EMA indication
- 2022-12-09: Initial authorization in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.
Also known as
- Generic names: Lutetium-177-PSMA-617, Lutetium PSMA
- Brand name: Pluvicto